Torbay Pharmacy Manufacturing Unit appoints md

Dr Nick Frampton to run the unit

The UK’s South Devon Healthcare NHS Foundation Trust has appointed Dr Nick Frampton as managing director of the Torbay Pharmacy Manufacturing Unit (PMU), which produces licensed pharmaceuticals, pharmaceutical specials and medical devices.

Frampton joins the firm from Advanced Medical Solutions Group, where he was vice president of sales and marketing and contributed to a period of double-digit growth. He has formerly held quality, technical and commercial roles at West Pharmaceutical Services, Ernest Jackson and Banner Pharmacaps.

You may also like

Finance

NorthEdge invests in sterile injectable CMO to accelerate international growth

Private equity firm NorthEdge has invested in sterile injectable contract manufacturer and licence holder, Torbay Pharmaceuticals (Torbay), to support its next phase of international growth
Manufacturing

Viatris to cut 10% of its global workforce after Indian plant fire

Viatris has lowered its profit outlook for 2026 after a fire in February shut down a key plant in Nashik, India. Despite this, the company reported stronger-than-expected revenue and announced a restructuring plan
Finance

Heligan Group report: UK healthcare M&A remains resilient

A new report from the investment group has highlighted the healthcare field as being a "defensive, structurally supported sector"
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Procurement as a strategic business enabler

How Alkermes unlocked $30m in project cost savings with JAGGAER
Finance

Axol Bioscience expands ophthalmology portfolio with acquisition of Newcells Biotech business

Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, strengthening its iPSC-derived retinal organoid and RPE model offerings
Finance

Gilead Sciences to acquire Arcellx in $7.8 billion deal to advance Anito-cel

Gilead Sciences has agreed to acquire Arcellx for $7.8bn, gaining full control of investigational CAR T therapy anito-cel following FDA acceptance of its BLA for relapsed/refractory multiple myeloma
You need to be a subscriber to read this article.
Click here to find out more.
Finance

Lario Therapeutics secures $2.4m from MJFF and Wellcome to expand CNS calcium channel programmes

The company has been awarded $2.4m in grant funding from The Michael J. Fox Foundation for Parkinson's Research and Wellcome to advance its neuronal calcium channel platform into Parkinson's disease and post-traumatic stress disorder
Subscribe now